Aimwell runs four independent audit agents against every brief and returns one verdict — PROCEED, DELAY, or KILL — so VP Regulatory, VP BD, Investment Committee, and Clinical Research all operate on validated intelligence, not AI-generated assumptions.
“97% of your market is not ready to buy today. That doesn’t mean they won’t buy. It means they need to be educated first.”
— Chet Holmes, The Ultimate Sales Machine
Most biopharma organizations are not in the market for a new intelligence platform today. They’re in the middle of a trial, a filing, a deal. They have tools that mostly work. They will not switch until the cost of not switching becomes undeniable.
AimwellBio is built for the 97%. We are not here to pitch you. We are here to make sure that when the moment comes — the failed filing, the missed acquisition window, the competitor that moved first — you already understand what AimwellBio does and why the difference matters.
Your CSO is making portfolio decisions based on intelligence that was current three weeks ago. A competitor acquisition closed yesterday. A regulatory pathway shifted last Friday. The board meeting is Thursday. Cortex is built so leadership operates on regularly updated strategic intelligence — not last month's assumptions.
Delivers: Strategic briefings, competitive landscape monitoring, portfolio intelligence, board-ready summaries.
The licensing window for that Phase 2 asset opened 11 days ago. Two competitors already know. Your BD team will find out in a conference hallway next quarter — unless Cortex tells them first. It is already monitoring deal flow, partnership signals, and asset availability across your target landscape.
Delivers: Partner monitoring, deal landscape tracking, asset comparison, licensing signals.
A competitor's Phase 2b readout just changed the competitive landscape in your therapeutic area. Your research lead will read about it in a journal next month. Cortex detected it as it surfaced and is already mapping the implications for your pipeline positioning.
Delivers: Trial monitoring, scientific signals, therapeutic area intelligence, pipeline visibility.
An FDA guidance change can invalidate six months of filing preparation overnight. Most regulatory teams discover these shifts after the compliance pressure is already real. Cortex monitors FDA and EMA actions continuously and flags timeline-affecting changes before they cascade into operational disruption.
Delivers: FDA/EMA tracking, guidance monitoring, compliance alerts, filing timeline intelligence.
New therapies are approved. Clinical trials shift treatment protocols. Drug interactions emerge from post-market surveillance. The practitioners who see these signals first make better decisions for their patients. Cortex delivers structured, verified intelligence directly to your practice — continuously.
Available for qualified healthcare practitioners and clinical organizations.